Literature DB >> 23435963

Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer.

Natsue Uehiro1, Rie Horii, Takuji Iwase, Masahiko Tanabe, Takehiko Sakai, Hidetomo Morizono, Kiyomi Kimura, Kotaro Iijima, Yumi Miyagi, Seiichiro Nishimura, Masujiro Makita, Yoshinori Ito, Futoshi Akiyama.   

Abstract

BACKGROUND: The TNM classification of the Unio Internationalis Contra Cancrum was revised for the seventh edition. The major change concerning breast cancer is a change in the stages for patients with T0 or T1N1miM0. In the present study, the seventh edition of the TNM classification was validated in breast cancer.
METHODS: The stages of 416 breast cancer patients, treated at our hospital in 1996, were classified according to the TNM classification, sixth and seventh editions, and their prognoses were compared.
RESULTS: Case distribution using the sixth edition was stage 0, 56 cases (13.5 %); stage I, 158 cases (38.0 %); stage II, 130 [A, 102; B, 28] cases (31.2 [A, 24.5; B, 6.7] %); and stage III, 72 [A, 31; B, 8; C, 33] cases (17.3 [A, 7.5; B, 1.9; C, 7.9] %). According to the seventh edition, the stages for 20 patients, accounting for 19.6 % of IIA cases according to the sixth edition, decreased from IIA to IB. The 10-year overall survivals were stage 0, 91.1 %; stage I, 88.6 %; stage II, 80.8 %; and stage III, 63.9 % according to the sixth edition; and stage 0, 91.1 %; stage I, 88.8 %; stage II, 79.1 %; and stage III, 63.9 % according to the seventh edition. Although no significant differences were seen among the survival rates for stages 0 to II according to the sixth edition, there was a significant difference between stage I and II according to the seventh edition (p = 0.026).
CONCLUSION: The latest revision of the TNM classification is appropriate for breast cancer from the perspective of prognosis.

Entities:  

Mesh:

Year:  2013        PMID: 23435963     DOI: 10.1007/s12282-013-0453-7

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  5 in total

1.  Association of five single nucleotide polymorphisms at 6q25.1 with breast cancer risk in northwestern China.

Authors:  Long Zhou; Na He; Tian Feng; Tingting Geng; Tianbo Jin; Chao Chen
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Prognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging.

Authors:  Ying Li; Xi Wei; Sheng Zhang; Jin Zhang
Journal:  Tumour Biol       Date:  2015-06-09

3.  Presentation of the Molecular Subtypes of Breast Cancer Detected By Immunohistochemistry in Surgically Treated Patients.

Authors:  Borislav Kondov; Zvonko Milenkovikj; Goran Kondov; Gordana Petrushevska; Neli Basheska; Magdalena Bogdanovska-Todorovska; Natasha Tolevska; Ljube Ivkovski
Journal:  Open Access Maced J Med Sci       Date:  2018-06-06

4.  The novel sugar transporter SLC50A1 as a potential serum-based diagnostic and prognostic biomarker for breast cancer.

Authors:  Yu Wang; Yao Shu; Congyang Gu; Yu Fan
Journal:  Cancer Manag Res       Date:  2019-01-17       Impact factor: 3.989

Review 5.  Relationship of clinical and pathologic nodal staging in locally advanced breast cancer: current controversies in daily practice?

Authors:  Francesca De Felice; Daniela Musio; Nadia Bulzonetti; Nicola Raffetto; Vincenzo Tombolini
Journal:  J Clin Med Res       Date:  2014-09-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.